Table 1.
Baseline characteristics of the patients
| Characteristics | Zabofloxacin (n=175) (%) | Moxifloxacin (n=167) (%) | P-value |
|---|---|---|---|
| Age, years | 67.8±7.8 | 68.4±8.0 | 0.46 |
| Sex, male | 153 (87.4) | 159 (95.2) | 0.01 |
| Height, cm | 162.9±6.5 | 164.1±6.3 | 0.10 |
| Weight, kg | 59.8±11.1 | 58.7±9.6 | 0.33 |
| Smoking history | <0.01 | ||
| Current | 50 (28.6) | 38 (22.8) | |
| Ex | 107 (61.1) | 126 (75.5) | |
| Never | 18 (10.3) | 3 (1.8) | |
| Alcohol | 0.29 | ||
| Never | 26 (14.9) | 21 (12.6) | |
| Ex | 91 (52.0) | 101 (60.5) | |
| Current | 58 (33.1) | 45 (27.0) | |
| Chronic bronchitis | 65 (37.1%) | 71 (42.5%) | 0.31 |
| PFT (post-BD) | |||
| FVC (L) | 2.9±0.8 | 3.1±0.7 | 0.10 |
| FVC (%) | 74.9±17.0 | 76.5±16.7 | 0.40 |
| FEV1 (L) | 1.4±0.5 | 1.4±0.5 | 0.93 |
| FEV1 (%) | 50.5±18.1 | 49.1±17.2 | 0.51 |
| FEV1/FVC (%) | 47.8±12.7 | 45.2±12.6 | 0.07 |
| Dyspnea | 0.60 | ||
| Mild | 27 (15.4) | 25 (15.0) | |
| Moderate | 113 (64.6) | 101 (60.5) | |
| Severe | 35 (20.0) | 41 (24.6) | |
| Comorbidity | |||
| Ischemic heart disease | 13 (7.4) | 14 (8.4) | 0.74 |
| Congestive heart failure | 12 (6.9) | 7 (4.2) | 0.28 |
| Cerebrovascular disease | 7 (4.0) | 3 (1.8) | 0.34 |
| Diabetes mellitus | 15 (8.6) | 18 (10.8) | 0.49 |
| Hypertension | 50 (28.6) | 48 (28.7) | 0.97 |
| Osteoporosis | 11 (6.3) | 6 (3.6) | 0.25 |
| Hyperlipidemia | 14 (8.0) | 9 (5.4) | 0.34 |
| Concomitant medication | |||
| Systemic steroid during exacerbation | 81 (46.3) | 85 (50.9) | 0.39 |
| LABA | 17 (9.7) | 28 (16.8) | 0.05 |
| LAMA | 116 (66.3) | 118 (70.7) | 0.38 |
| ICS | 9 (5.1) | 9 (5.4) | 0.92 |
| ICS + LABA | 99 (56.6) | 89 (53.3) | 0.54 |
| Theophylline | 29 (16.6) | 21 (12.6) | 0.30 |
| PDE4I | 9 (5.1) | 12 (7.2) | 0.43 |
| Symptom score on Day 1 | |||
| EXACT-PRO | 45.5±9.6 | 46.7±11.9 | 0.31 |
| CAT | 22.6±7.0 | 23.2±7.6 | 0.45 |
Note: Data are expressed as mean ± standard deviation or as number (percentage) of patients.
Abbreviations: PFT, pulmonary function test; BD, bronchodilator; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; PDE4I, phosphodiesterase 4 inhibitor; EXACT-PRO, EXAcerbations of Chronic Pulmonary Disease Tool-Patient-Reported Outcome; CAT, chronic obstructive pulmonary disease assessment test.